Gossamer Bio Faces Securities Litigation Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GOSS?
Source: PRnewswire
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., specifically for investors who purchased securities between June 16, 2025, and February 20, 2026, urging them to seek lead plaintiff status by the June 1, 2026 deadline.
- Clinical Trial Failure: On February 23, 2026, Gossamer Bio revealed adverse topline results from its Phase 3 PROSERA study, failing to meet the primary endpoint of improving six-minute walk distance at Week 24, with a placebo-adjusted gain of +13.3 meters that did not achieve statistical significance, leading to a loss of investor confidence.
- Stock Price Plummets: Following the trial results announcement, Gossamer's stock price collapsed from $2.13 per share on February 20, 2026, to $0.42 per share, representing a decline of over 80% in a single trading day, reflecting extreme pessimism about the company's future.
- Legal Rights Reminder: Faruqi & Faruqi encourages anyone with information regarding Gossamer's conduct, including whistleblowers and former employees, to contact the firm directly to assist in potential class action litigation, ensuring that investors' legal rights are protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.372
Low
10.00
Averages
12.33
High
15.00
Current: 0.372
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., specifically for investors who purchased securities between June 16, 2025, and February 20, 2026, urging them to seek lead plaintiff status by the June 1, 2026 deadline.
- Clinical Trial Failure: On February 23, 2026, Gossamer Bio revealed adverse topline results from its Phase 3 PROSERA study, failing to meet the primary endpoint of improving six-minute walk distance at Week 24, with a placebo-adjusted gain of +13.3 meters that did not achieve statistical significance, leading to a loss of investor confidence.
- Stock Price Plummets: Following the trial results announcement, Gossamer's stock price collapsed from $2.13 per share on February 20, 2026, to $0.42 per share, representing a decline of over 80% in a single trading day, reflecting extreme pessimism about the company's future.
- Legal Rights Reminder: Faruqi & Faruqi encourages anyone with information regarding Gossamer's conduct, including whistleblowers and former employees, to contact the firm directly to assist in potential class action litigation, ensuring that investors' legal rights are protected.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of securities laws, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026, for participation.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning placebo response controls at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, demonstrating the firm's commitment to protecting shareholder interests.
See More
Class Action Lawsuits Filed for Multiple Companies
- Gossamer Bio Lawsuit: Shareholders of Gossamer Bio have filed a class action lawsuit due to the company's failure to disclose critical clinical trial results from June 2025 to February 2026, with a lead plaintiff deadline of June 1, 2026, potentially impacting the company's reputation and stock price.
- New Era Energy Lawsuit: New Era Energy shareholders have initiated a class action lawsuit alleging that the company overstated project progress and engaged in fraudulent activities from November 2024 to December 2025, with the same deadline of June 1, 2026, which may lead to decreased investor confidence.
- Medpace Holdings Lawsuit: Shareholders of Medpace have filed a class action lawsuit due to the company's inaccurate business projections from April 2025 to February 2026, with a lead plaintiff deadline of June 5, 2026, potentially negatively affecting the company's future financing capabilities.
- Stellantis Lawsuit: Stellantis shareholders have initiated a class action lawsuit alleging that the company failed to accurately disclose the realities of the electric vehicle market from February 2025 to February 2026, with a lead plaintiff deadline of June 8, 2026, which may impact the company's competitiveness in the EV sector.
See More
Class Action Lawsuit Filed Against Gossamer Bio by Shareholders
- Class Action Initiation: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit on behalf of shareholders who purchased Gossamer Bio (NASDAQ:GOSS) securities between June 16, 2025, and February 20, 2026, with a deadline for lead plaintiff applications set for June 1, 2026, highlighting significant concerns over the company's financial transparency.
- Allegations of Misrepresentation: The filed complaint alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts regarding the company's business, operations, and prospects, indicating severe deficiencies in corporate governance and information disclosure.
- Clinical Trial Failure: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in an 80.3% stock price drop, which triggered a crisis of confidence among investors regarding the company's future.
- Law Firm's Background: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP boasts over 125 years of legal expertise in securities litigation, dedicated to pursuing justice for investors harmed by misrepresentations, showcasing its professionalism and reliability in protecting investor rights.
See More
Class Action Filed Against Gossamer Bio for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, seeking damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegations: The complaint alleges that Gossamer Bio made materially false and misleading statements during the class period, failing to disclose significant flaws in the design of its Phase 3 PROSERA study, which led investors to buy shares at artificially inflated prices.
- Investor Losses: The lawsuit claims that due to the failure to adequately control for placebo response at Latin American testing sites, Gossamer's securities traded at inflated levels, resulting in losses for investors, with the lawsuit aiming to recover these damages.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they are successful, thereby reducing the financial burden on investors pursuing the lawsuit.
See More
Gossamer Bio Investors Reminder for Upcoming Lawsuit Deadline
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 1, 2026, to participate in the class action regarding losses incurred from Gossamer Bio (NASDAQ:GOSS) securities purchased between June 16, 2025, and February 20, 2026.
- Stock Price Plunge: On February 23, 2026, Gossamer's stock plummeted by $1.71, or 80.3%, closing at $0.42 per share after the company disclosed that its Phase 3 PROSERA study failed to meet its primary endpoint, significantly harming investors.
- False Statements Allegation: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose critical information about the treatment of patients in Latin America, leading to misleading assessments of the company's prospects.
- Legal Consultation Channels: Investors can contact the Law Offices of Howard G. Smith via email or phone to learn about their rights and the process for participating in the lawsuit, ensuring their legal interests are protected.
See More
Gossamer Bio Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc., specifically for investors who purchased securities between June 16, 2025, and February 20, 2026, urging them to seek lead plaintiff status by the June 1, 2026 deadline.
- Clinical Trial Failure: On February 23, 2026, Gossamer Bio revealed adverse topline results from its Phase 3 PROSERA study, failing to meet the primary endpoint of improving six-minute walk distance at Week 24, with a placebo-adjusted gain of +13.3 meters that did not achieve statistical significance, leading to a loss of investor confidence.
- Stock Price Plummets: Following the trial results announcement, Gossamer's stock price collapsed from $2.13 per share on February 20, 2026, to $0.42 per share, representing a decline of over 80% in a single trading day, reflecting extreme pessimism about the company's future.
- Legal Rights Reminder: Faruqi & Faruqi encourages anyone with information regarding Gossamer's conduct, including whistleblowers and former employees, to contact the firm directly to assist in potential class action litigation, ensuring that investors' legal rights are protected.
See More
Gossamer Bio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio for violations of securities laws, concerning securities purchased between June 16, 2025, and February 20, 2026, with a deadline to contact the firm by June 1, 2026, for participation.
- False Statements Allegation: The complaint alleges that Gossamer concealed adverse facts regarding the design of its Phase 3 PROSERA study, particularly concerning placebo response controls at certain testing sites, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: As the market learned the truth about Gossamer, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, demonstrating the firm's commitment to protecting shareholder interests.
See More
Class Action Lawsuits Filed for Multiple Companies
- Gossamer Bio Lawsuit: Shareholders of Gossamer Bio have filed a class action lawsuit due to the company's failure to disclose critical clinical trial results from June 2025 to February 2026, with a lead plaintiff deadline of June 1, 2026, potentially impacting the company's reputation and stock price.
- New Era Energy Lawsuit: New Era Energy shareholders have initiated a class action lawsuit alleging that the company overstated project progress and engaged in fraudulent activities from November 2024 to December 2025, with the same deadline of June 1, 2026, which may lead to decreased investor confidence.
- Medpace Holdings Lawsuit: Shareholders of Medpace have filed a class action lawsuit due to the company's inaccurate business projections from April 2025 to February 2026, with a lead plaintiff deadline of June 5, 2026, potentially negatively affecting the company's future financing capabilities.
- Stellantis Lawsuit: Stellantis shareholders have initiated a class action lawsuit alleging that the company failed to accurately disclose the realities of the electric vehicle market from February 2025 to February 2026, with a lead plaintiff deadline of June 8, 2026, which may impact the company's competitiveness in the EV sector.
See More
Class Action Lawsuit Filed Against Gossamer Bio by Shareholders
- Class Action Initiation: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit on behalf of shareholders who purchased Gossamer Bio (NASDAQ:GOSS) securities between June 16, 2025, and February 20, 2026, with a deadline for lead plaintiff applications set for June 1, 2026, highlighting significant concerns over the company's financial transparency.
- Allegations of Misrepresentation: The filed complaint alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts regarding the company's business, operations, and prospects, indicating severe deficiencies in corporate governance and information disclosure.
- Clinical Trial Failure: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in an 80.3% stock price drop, which triggered a crisis of confidence among investors regarding the company's future.
- Law Firm's Background: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP boasts over 125 years of legal expertise in securities litigation, dedicated to pursuing justice for investors harmed by misrepresentations, showcasing its professionalism and reliability in protecting investor rights.
See More
Class Action Filed Against Gossamer Bio for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Gossamer Bio, seeking damages for investors who purchased securities between June 16, 2025, and February 20, 2026, highlighting potential violations of federal securities laws.
- False Statements Allegations: The complaint alleges that Gossamer Bio made materially false and misleading statements during the class period, failing to disclose significant flaws in the design of its Phase 3 PROSERA study, which led investors to buy shares at artificially inflated prices.
- Investor Losses: The lawsuit claims that due to the failure to adequately control for placebo response at Latin American testing sites, Gossamer's securities traded at inflated levels, resulting in losses for investors, with the lawsuit aiming to recover these damages.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they are successful, thereby reducing the financial burden on investors pursuing the lawsuit.
See More
Gossamer Bio Investors Reminder for Upcoming Lawsuit Deadline
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 1, 2026, to participate in the class action regarding losses incurred from Gossamer Bio (NASDAQ:GOSS) securities purchased between June 16, 2025, and February 20, 2026.
- Stock Price Plunge: On February 23, 2026, Gossamer's stock plummeted by $1.71, or 80.3%, closing at $0.42 per share after the company disclosed that its Phase 3 PROSERA study failed to meet its primary endpoint, significantly harming investors.
- False Statements Allegation: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose critical information about the treatment of patients in Latin America, leading to misleading assessments of the company's prospects.
- Legal Consultation Channels: Investors can contact the Law Offices of Howard G. Smith via email or phone to learn about their rights and the process for participating in the lawsuit, ensuring their legal interests are protected.
See More
